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Abstract
Introduction: Antiretroviral therapy (ART) substantially improves the health of people living with HIV and contributes to
preventing new infections. While HIV incidence is decreasing in most regions, the epidemic in eastern Europe continues to rise,
as new infections currently outnumber the rate of ART initiation. In this study, we assess ART use in Armenia and its impact on
the number of AIDS diagnoses and mortality.
Methods: National surveillance data were obtained from the National Centre for AIDS Prevention, Armenia. Cox-proportional
hazard models were used to determine the effect of demographic and clinical risk factors, including access to ART, on AIDS and
mortality.
Results: Among people diagnosed with HIV since 2005, approximately 40% per year were diagnosed with CD4B200 cells per
mL. Overall, 232 people (57.1%) with AIDS or a low CD4 count had not received ART by the end of 2010. Mortality was 34.1%
among people living with HIV who did not initiate ART, and 0.3% among people who received ART. Among people diagnosed
with HIV from 1996 to 2010, age at diagnosis, no use of ART, likely mode of transmission, likely place of transmission, low
baseline CD4 count and no STI diagnosis at last contact are significantly associated with death.
Discussion: In Armenia, HIV is frequently diagnosed at a late stage of disease, indicating low testing rates. Of people diagnosed
with HIV and in need of ART, a large proportion (approximately 60%) either do not provide consent for treatment, or are who
migrants who cannot be located.
Conclusions: Globally, the scale-up of ART has resulted in substantial reductions in mortality among individuals initiating therapy.
However, in an era of momentum for treatment as prevention, treatment levels are not at adequate levels for preventing
morbidities and mortality in some settings. Particular focus should be placed on key at-risk subgroups.
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Introduction
Eastern Europe and central Asia is the only region of the world
where HIV incidence and AIDS-related deaths continue to
increase [13]. From 2001 to 2010, the number of people
living with HIV (PLHIV) in the region has risen by 250% [4]. The
region is characterised by concentrated epidemics, predomi-
nantly among injecting drug users (IDUs) [1]. Rates of HIV
are also high among other priority populations such as sex
workers, men who have sex with men and migrant labourers
[2]. Heterosexual transmission of HIV to the partners of IDUs
and migrant workers is cause for concern that an epidemic
in the region may become more generalised [5].
The increased burden of HIV in eastern Europe and central
Asia is driven by poor access to antiretroviral therapy (ART)
[2]. Combination ART first became available from 1996, with
high coverage in developed countries [6]. A push for expanded
access to ART in low- and middle-income countries occurred
in early to mid-2000s, particularly with the World Health
Organisations’ ‘‘3 by 5’’ initiative, which aimed to have three
million people on ART by 2005 [7]. However, in practice, wide
scale-up of ART access took place in these countries from
20062010, and in 2012, more than seven million PLHIVs had
access to ART [6]. Universal coverage of timely ART among
people in need reduces HIV-related morbidity and is emerging
as a key prevention strategy [8,9]. However, in regions such
as eastern Europe and central Asia, ART coverage has not
achieved sufficient levels to sustain life among PLHIV [6].
In this study we analyse HIV and AIDS in the Republic of
Armenia, a country representative of the epidemic in lower-
and middle-income countries of eastern Europe and central
Asia. Armenia has a population of three million people, with
an estimated national HIV prevalence of 0.1% [2]. While most
HIV infections in Armenia are attributable to heterosexual
transmission, the HIV epidemic is also highly concentrated
among IDUs with an estimated prevalence of 9.5% [2,10].
Armenia has a small, but rigorous and centralised, HIV/AIDS
data collection system. ART first became available in Armenia
in 2005 [10]. The aim of this paper is to assess the effect of
ART coverage on AIDS diagnoses and mortality in the Republic
of Armenia and to infer the adequacy of HIV testing rates.




The number of people who had received ART each year since
2005 was extracted from surveillance data, and this was
compared to the number of people who were eligible for
ART. During the period of this study, eligibility for ART was
defined in the Armenian National HIV/AIDS Treatment and
Care Protocols as meeting at least one of the following
criteria at diagnosis: a) the presence of clinical AIDS; b) CD4
count B200 cells per mL; or c) CD4 count B350 cells per mL
if symptoms were present.
National HIV surveillance data were available from the
National Center for AIDS Prevention (NCAP) in Armenia, from
1988 to 2010. NCAP is responsible for collecting all HIV testing
data in Armenia, including outcomes from all processing of
blood samples and the maintenance of a centralised national
HIV surveillance database. These data include demographic
and clinical information on people diagnosed with HIV, in-
cluding age; sex; marital status; date of HIV, AIDS and death
diagnoses; location of residence (marz, the highest adminis-
trative boundary); self-reported likely mode of transmission,
self-reported place and date of likely transmission; presence
of an sexually transmissible infection (STI); use of ART; and
CD4 count at diagnosis. AIDS and STI diagnosis are reported
at last contact. STI diagnoses were obtained by laboratory
confirmation.
A retrospective cohort analysis of HIV and AIDS in the
Republic of Armenia was conducted. Data from people diag-
nosed with HIV from January 1996 were used. Follow-up time
was from date of HIV diagnosis to AIDS diagnosis, death or
31 December 2010. Demographic and clinical data are pre-
sented as frequencies and percentages for categorical data,
or medians and interquartile ranges for continuous data.
Cox proportional hazards modelling was used to determine
whether these clinical and demographic risk factors were
significantly associated with the development of AIDS and
all-cause mortality, among people who are diagnosed with
HIV in Armenia. Backwards stepwise modelling was used, and
all variables which were significant at the p0.2 level in
univariate models were included in multivariate analyses.
The threshold for significance in multivariate models was
p0.05. Age and sex were retained in the multivariate models
regardless of statistical significance. The age group 2029 was
chosen as the reference category, as it is the youngest age
group with sufficient numbers of PLHIV to ensure statistical
Table 1. Demographic and clinical descriptive statistics (at diagnosis) by AIDS diagnosis and death (at last contact), among those












Total n 968 491 477 733 235
Age (years) 019 35 (3.6) 22 (4.5) 13 (2.7) 28 (3.8) 7 (3.0)
2029 275 (28.4) 175 (35.6) 100 (21.0) 238 (32.5) 37 (15.7)
3039 380 (39.3) 169 (34.4) 211 (44.2) 281 (38.3) 99 (42.1)
4049 218 (22.5) 97 (19.8) 121 (25.4) 145 (19.8) 73 (31.1)
50 60 (6.2) 28 (5.7) 32 (6.7) 41 (5.6) 19 (8.1)
Sex Male 695 (71.8) 329 (67.0) 366 (76.7) 500 (68.2) 195 (83.0)
Female 273 (28.2) 162 (33.0) 111 (23.3) 233 (31.8) 40 (17.0)
Marital status Single 170 (17.6) 87 (17.7) 83 (17.4) 127 (17.3) 43 (18.3)
Married 391 (40.4) 186 (37.9) 205 (43.0) 304 (41.5) 87 (37.0)
Other 88 (9.0) 38 (7.7) 50 (10.5) 65 (8.9) 23 (9.8)
Unknown 319 (33.0) 180 (36.7) 139 (29.1) 237 (32.3) 82 (34.9)
Mode of transmission Heterosexual 497 (51.3) 286 (58.2) 211 (44.2) 404 (55.1) 93 (39.6)
IDU 384 (39.7) 152 (31.0) 232 (48.6) 259 (35.3) 125 (53.2)
Othera 37 (3.8) 21 (4.3) 16 (3.4) 28 (3.8) 9 (3.8)
Unknown 50 (5.2) 32 (6.5) 18 (3.8) 42 (5.7) 8 (3.4)
Place of transmission Armenia 244 (25.2) 134 (27.3) 110 (23.1) 198 (27.0) 46 (19.6)
Russia 404 (41.7) 181 (36.9) 223 (46.8) 303 (41.3) 101 (43.0)
Other 85 (8.8) 28 (5.7) 57 (11.9) 59 (8.0) 26 (11.1)
Unknown 235 (24.3) 148 (30.1) 87 (18.2) 173 (23.6) 62 (26.4)
Location (marz) Yerevan 407 (42.0) 189 (38.5) 218 (45.7) 301 (41.1) 106 (45.1)
Other 551 (57.0) 292 (59.5) 259 (54.3) 423 (57.7) 128 (54.5)
Unknown 10 (1.0) 10 (2.0) 0 (0.0) 9 (1.2) 1 (0.4)
Presence of an STI No 784 (81.1) 430 (87.6) 354 (74.2) 555 (75.7) 229 (97.4)
Yes 184 (18.9) 61 (12.4) 123 (25.8) 178 (24.3) 6 (2.6)
CD4 count at diagnosis Median (IQR) 277 (87497) 492 (378647) 128 (42269) 330 (127515) 110 (39281)
aOther modes of transmission include: men who have sex with men, children of mothers living with HIV and blood and organ recipients.
Mallitt K-A et al. Journal of the International AIDS Society 2014, 17:18795
http://www.jiasociety.org/index.php/jias/article/view/18795 | http://dx.doi.org/10.7448/IAS.17.1.18795
2
precision of estimates. Kaplan-Meier curves were used to
visualise the risk of death stratified by important signi-
ficant variables. All statistical analyses were conducted in
Stata v.12.
Results
From 1996 to 2010 there were 968 reported cases of HIV, and
477 cases of AIDS. From 1996 to 2003, the number of HIV
diagnoses in the Republic of Armenia remained low, at below
40 per year. From 2003 to present there has been a sub-
stantial rise in HIV diagnoses, with more than 140 cases
diagnosed in 2010. The number of AIDS diagnoses in Armenia
has followed a similar pattern. AIDS diagnoses remained at
below 20 per year from 1996 to 2003, followed by an increase
to 2010. Among PLHIV who develop AIDS, the median time
between HIV diagnosis and AIDS diagnosis is 70 days, and for
those who die, the median time to death after HIV diagnosis
is 163 days.
Demographic and clinical characteristics of people diag-
nosed with HIV in Armenia (19962010), stratified by AIDS
diagnosis and death, are shown in Table 1. The majority of
people diagnosed with HIV were male (71.8%), aged 3039
years (39.3%) and married (40.4%). The most common
reported mode of HIV transmission was heterosexual contact
(51.3%); and 39.7% were reported as IDUs. People who were
diagnosed with AIDS (48.6%) or who died (53.2%) were dis-
proportionately more likely to be IDUs. Only 25.2% of people
diagnosed with HIV acquired HIV within Armenia, and the
most common country of HIV acquisition was the Russian
Federation (41.7%). Armenia’s capital city of Yerevan was the
most common location of residence at HIV diagnosis (42%),
with other substantial numbers of cases in Shirak (11.1%),
Lori (9.5%) and Armavir (9.0%). Among people diagnosed
with HIV, 18.9% were also diagnosed with another STI.
However, only 2.6% of people who died had been diagnosed
with an STI.
From 2005 (when ART became available in Armenia) to
2010, approximately 25% of people diagnosed with HIV had a
baseline CD4 count of greater than 500 cells per mL. However,
40% of people who are diagnosed with HIV each year had
Figure 1. Baseline CD4 count (percentage) among people diagnosed with HIV in Armenia (20052010).
Table 2. Number of people diagnosed with HIV (20052010) in Armenia who were ‘‘eligible’’a for ART, by whether they had
received ART to either the end of 2010 or to time of death















2005 15 (35.7) 27 (64.3) 42 (100) 1 (3.0) 32 (97.0) 33 (100) 75 29
2006 19 (54.3) 16 (45.7) 35 (100) 3 (9.4) 29 (90.6) 32 (100) 67 24
2007 29 (44.6) 36 (55.4) 65 (100) 5 (11.9) 37 (88.1) 42 (100) 107 26
2008 38 (50.0) 38 (50.0) 76 (100) 4 (6.7) 56 (93.3) 60 (100) 136 36
2009 38 (39.2) 59 (60.8) 97 (100) 7 (13.5) 45 (86.5) 52 (100) 149 19
2010 35 (38.5) 56 (61.5) 91 (100) 3 (5.3) 54 (94.7) 57 (100) 148 19
Overall 174 (42.9) 232 (57.1) 406 (100) 23 (8.3) 253 (91.7) 276 (100) 682 153
aPersons eligible for ART meet at least one of the following at diagnosis: a) the presence of clinical AIDS; b) CD4 count B200/mL; or c) CD4 count
B350/mL if symptoms are present.
bTo the end of December, 2010.
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a baseline CD4 count of B200 cells per mL. These proportions
were fairly consistent from 2005 to 2010 (Figure 1). Prior
to 2005, 101 people (35.3% of HIV diagnoses) had a baseline
CD4 count recorded. From 2005 to 2010, this figure rose to
535 people (78.5% of HIV diagnoses). Since 2005, the median
CD4 count among was 121.5 cells per mL (IQR 238) among
people who were eligible for ART, and 503 (IQR 283) for those
who were not eligible.
Table 3. Cox proportional hazards survival analysis of the effect of clinical and demographic risk factors on time to AIDS and time to












Time to AIDS Age (in years) 019 1.11 (0.621.98) 1.73 (0.933.25)
diagnosis 2029 1 B0.001 1 0.002
3039 1.93 (1.522.45) 1.40 (1.071.81)
4049 1.98 (1.522.58) 1.71 (1.282.30)
50 2.18 (1.463.25) 2.04 (1.303.19)
Sex Male 1 0.001
Female 0.76 (0.611.93)













Place of residence Yerevan 1 0.329
Other 0.91 (0.761.10)
STI No 1 B0.001
Yes 1.74 (1.422.14)
Baseline CD4 Per 100 cells/mL 0.58 (0.550.62) B0.001 0.59 (0.550.63) B0.001
Time to death Age (in years) 019 1.50 (0.673.37) 3.63 (0.9913.4)
2029 1 B0.001 1 0.002
3039 2.25 (1.543.28) 1.30 (0.762.23)
4049 3.23 (2.174.80) 2.25 (1.273.99)
50 3.65 (2.096.37) 3.60 (1.508.65)
Sex Male 1 B0.001
Female 0.52 (0.370.73)
Marital status Single 1 0.910
Married 0.84 (0.651.34)
Other/unknown 0.98 (0.671.40)
Likely mode of Sexual contact 1 B0.001 1 0.040
transmission IDU 1.70 (1.302.22) 1.61 (1.062.43)
Other/unknown 1.01 (0.601.70) 0.60 (0.191.91)
Likely place of Armenia 1 0.242 1 0.016
transmission Russia 1.32 (0.931.87) 0.80 (0.491.32)
Other/unknown 1.10 (0.771.59) 0.45 (0.250.80)
Place of residence Yerevan 1 0.808
Other 1.03 (0.801.34)
STI No 1 B0.001 1 0.045
Yes 0.10 (0.050.23) 0.42 (0.180.98)
Baseline CD4 Per 100 cells/mL 0.72 (0.650.79) B0.001 0.61 (0.550.69) B0.001
ART use No 1 B0.001 1 B0.001
Yes 0.01 (0.000.06) 0.01 (0.000.05)
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Table 2 shows the number of people who met one of
the three eligibility criteria for ART (used during the period
of this study) in each year from 2005 to 2010 and indicates
how many of these eligible people received ART to the end of
2010. Among those diagnosed with HIV since 2005, 232
eligible people (57.1%) had not received ART by the end of
2010. This ranges from 64.3% in 2005 to 50% in 2008.
Age (p0.002) and baseline CD4 count (pB0.001)
were significantly associated with the development of AIDS
(Table 3). For every 100 cells per mL increase in CD4 at
diagnosis, PLHIV were 0.57 times less likely to develop AIDS
(95% CI 0.530.61).
Age (p0.002), likely mode of transmission (0.040), likely
place of transmission (0.016), no use of ART (pB0.001),
baseline CD4 count (pB0.001) and STI diagnosis (p0.045)
were significantly associated with death among people diag-
nosed with HIV (19962010) (Table 3). ARTuse was associated
with 99% lower risk of mortality than those who did not have
access to ART (95% CI 0.000.05). The survival curve for the
hazard of death stratified by ART use is shown in Figure 2.
Among the 282 people who received ART, one person (0.3%)
died; while mortality was 34.1% among people who did
not receive ART (234 out of 686 people). The presence of an
STI was associated with a reduction in all-cause mortality
(HR0.42; 95% CI: 0.180.98).
Discussion
The rate of mortality among people diagnosed with HIV
in Armenia (19962010) is very high, and overall there is
low coverage of ART. It can be inferred that testing rates
are also low, as there is a consistently low median CD4 count
at diagnosis over time. People who receive ART are 99% less
likely to die than people who do not receive ART.
Among people diagnosed with HIV from 1996 to 2010,
age and baseline CD4 counts were significantly associated
with the development of AIDS. Age, mode of transmission,
place of transmission, no use of ART, low baseline CD4 count
and no STI diagnosis are significantly associated with death.
It is likely that the high mortality among people without a
clinical diagnosis of an STI is associated with a high rate of
undiagnosed STIs. People who have STIs that are more en-
gaged with the health system are more likely to be diagnosed
early with HIV and treated appropriately. A limitation of this
data is that there may be loss to follow-up, resulting in in-
complete data on AIDS and mortality. However, the observed
number of AIDS diagnoses and deaths are likely to be an
underestimate of the true number. ART use was not included
in the multivariate analysis of risk factors for AIDS because in
Armenia approximately 50% of people received ART concur-
rently with their AIDS diagnosis, and 50% received ART after
their AIDS diagnosis.
From 2005 to 2010, median CD4 count at diagnosis has
remained low, at 273 per mL. These data indicate that people
are typically being diagnosedwith HIV in Armenia several years
after initial HIV infection. People diagnosed with HIV who
suffer severe adverse health outcomes (AIDS diagnosis and
death) are at an advanced stage of disease at the time of HIV
diagnosis. Based on evidence from another country in the
region, this is likely associated with low testing rates due to
clinical, social and demographic factors such as comorbidities,
poor access to health services and stigma [11]. Routine HIV
testing among pregnant women in Armenia is very high [10].
However, testing rates among key at-risk subpopulations, such
as IDUs and migrant workers, must be urgently addressed.
Individuals who are younger or older than 2029 years
at diagnosis have the highest mortality. This age group has
the lowest testing rate in Armenia, and may reflect the fact
that these individuals have poor engagement with the health-
care system, and poorer follow-up. However, men of this age
may also be more likely to be seasonal workers less, and thus
less likely to receive treatment. The percentage of IDUs who
received an HIV test in the past 12 months and who know the
Figure 2. Risk of mortality after HIV diagnosis in Armenia, stratified by ART use (19962010).
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results was 20% [12]. Seasonal migrant workers, particularly
to higher prevalence countries such as Ukraine and Russia,
are very common in Armenia with a general population HIV
prevalence of 1.6 and 1.1%, respectively [1,2,13]. Migration
can result in higher levels of commercial and casual sex [5,11].
Armenian women married to migrants are significantly more
likely to be diagnosed with an STI than those married to non-
migrants [13]. In the absence of additional testing and
treatment among these subpopulations, the HIV epidemic in
Armenia is expected to rise [1].
In all low- and middle-income countries globally, the av-
erage coverage of ART among those in need was 47% in 2010
and only 22% in low and middle-income countries in eastern
Europe and central Asia [2,14]. This is exacerbated among
vulnerable groups who remain more isolated from main-
stream public health services [11]. The majority of PLHIV in the
region are IDUs; however, they make up less than 25% of
people on ART [14]. HIV testing rates in eastern Europe and
central Asia are also very low [2]. Among people diagnosed
with HIV since 2005 in Armenia, 62.8% of people with AIDS
or a low CD4 count had not received ART by the end of 2010.
Armenia has reported achieving universal access to ART at
the end of 2007, offering treatment to at least 80% of patients
in need; and 100% coverage to PLHIV in need from 2007 to
2009 [15,16]. However, these figures do not include a large
proportion (approximately 60%) of PLHIV who meet the clin-
ical criteria for ART access, but who either do not provide
consent for treatment, or who are migrants who cannot be
located (S. Grigoryan, National AIDS Center Armenia, personal
communication, 2 November, 2011). Priorities for clinical care
of PLHIVmust encompass all aspects of the treatment cascade
where continuity is maintained through HIV diagnosis, linkage
to care, retention in care, ART access and treatment adher-
ence with suppressed virus [17]. The percentage of PLHIV who
are eligible for treatment, but who are not on ART, should be
associated with a lack of access to ART. ‘‘Lack of access’’ is a
broad term that encompasses not only whether a patient is
offered ART in a clinic, but also the capacity of records and
information systems to track patients if they relocate and
ensuring patients are referred and entered into an alternative
ARVclinic, the social pressures and stigmas that maymake ART
more or less desirable, and perceptions of other treatment
options. These are all access issues that require addressing in
order to translate universal offering of ART to true universal
coverage of ART. In Armenia, a framework for domestic
priorities has been established. The National Strategic Plan
on the Response to the HIV Epidemic in the Republic of
Armenia for 20122016 [18] has been developed. Impor-
tantly, a higher threshold of ART initiation has been accepted
(CD4 B350), as recommended by WHO guidelines [19].
Conclusions
Up to 2010, HIV-related mortality was high and ART coverage
was low. HIV treatment must be up-scaled in the Republic
of Armenia, and more broadly in eastern Europe and central
Asia, to halt the mortality and morbidity associated with HIV.
This would also have the secondary benefit of reducing the
spread of infection to others. Particular focus should be placed
on key at-risk subgroups, such as IDUs and migrant workers.
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